Optimising neurodevelopmental and psychosocial outcomes for survivors with CHD: a research agenda for the next decade

Erica Sood1,2, Jeffrey P Jacobs3,4, Bradley S Marino5

  • 1Nemours Cardiac Center, Alfred I. duPont Hospital for Children, Wilmington, DE, USA.

Insights

Survivors of congenital heart disease (CHD) face neurodevelopmental challenges impacting quality of life. This study outlines a research agenda to improve neuroprotection and interventions for better long-term outcomes.

Area of Science:

  • Pediatric Cardiology
  • Neurodevelopmental Disorders
  • Psychosocial Health

Background:

  • Congenital heart disease (CHD) survivors experience neurodevelopmental and psychosocial impairments affecting quality of life and independence.
  • Risk factors are multifactorial, including genetic, fetal, surgical, and social elements, necessitating comprehensive neuroprotection strategies.

Purpose of the Study:

  • To establish a 10-year research agenda for cardiac neurodevelopmental and psychosocial outcomes.
  • To identify critical knowledge gaps and guide future scientific investigation in the field.

Main Methods:

  • Convened international experts in cardiac neurodevelopment, psychosocial research, clinical care, and health disparities.
  • Formed seven multidisciplinary working groups focusing on key research domains.
  • Included patient and family stakeholders in agenda development.

Main Results:

  • Identified significant gaps in knowledge across all seven working group domains.
  • Defined critical research questions essential for advancing cardiac neurodevelopmental and psychosocial outcomes.
  • Highlighted the need for a structured research agenda to inform funding and collaborative efforts.

Conclusions:

  • A prioritized research agenda is crucial for advancing cardiac neurodevelopmental and psychosocial outcomes.
  • Addressing knowledge gaps will improve care, policy, and long-term outcomes for CHD survivors.
  • Collaborative research initiatives are vital to reduce the burden of CHD on individuals and society.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
107
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
88
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
83
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
128
Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
1.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
107